Verona Pharma PLC - clinical-stage biopharmaceutical company - Pretax loss in third quarter ended September 30 widens to USD22.2 million from USD15.7 million a year earlier. For nine-months to September, loss stretches to USD47.1 million from USD38.7 million.
Current stock price: 51.00 pence
Year-to-date change: down 18%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.